Conclusion of significant purchase orders
With reference to the current report no. 25/2020 (dated July 4, 2020) the Management Board of Selvita S.A. with its registered office in Krakow (“Company”) hereby announces that the Company obtained two additional purchase orders (POs) with a total value of EUR 1.423.293 (PLN 6.473.847 converted at the rate EUR 1 = PLN 4.5485) from a biotechnological company with its registered office in Europe (“Client”) under the framework agreement which was concluded between the above-mentioned parties on February 01, 2018. The subject of purchase orders is the provision of chemical synthesis services aimed at supporting development of the Client’s innovative projects.
Moreover, Company’s Management Board informs, with reference to the current report no. 02/2021 (dated January 4, 2021), that the Company’s affiliate – Fidelta d.o.o. (“Fidelta”) has received a purchase order dated January 01, 2021, under the framework agreement between Fidelta and the Client concluded on October 1, 2018. The value of the order amounts to EUR 2.510.761 (PLN 11.420.196 converted at the above-mentioned exchange rate). The scope of services that will be provided to the Client by Fidelta, include support of its drug discovery projects in the area of medicinal chemistry, in vitro pharmacology as well as in vitro and in vivo DMPK.
The total value of the services that will be provided by Selvita Group to the Client in 2021 will amount to EUR 3.934.054 (PLN 17.894.043 converted at the above-mentioned exchange rate).
Services will be executed throughout the entire 2021, starting from January 4, in Selvita’s laboratories in Poland and Fidelta’s laboratories in Croatia.
Taking into account the value of the purchase orders, as well as the fact of the expanded cooperation with the Client, the Company’s Management Board considers the orders to be significant for the implementation of Selvita Group’s long-term plans aiming at the expansion of its scope of services portfolio, and building its position on the international preclinical CRO (Clinical Research Organization) market.
Art. 17 par. 1 of MAR
Representatives of the Company:
- Edyta Jaworska – Management Board Member
- Mirosława Zydroń – Management Board Member